Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313255 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL6371301 | 0.88 | GAA (0.56) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL13832504 | 0.88 | L3MBTL1 (0.52) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL19385593 | 0.88 | L3MBTL1 (0.52) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL19932156 | 0.84 | L3MBTL1 (0.48) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL5466626 | 0.84 | L3MBTL1 (0.48) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL30661038 | 0.83 | ALDH1A1 (0.41) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL13195018 | 0.83 | ALDH1A1 (0.41) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL25009553 | 0.82 | GAA (0.61) | L3MBTL1POLBGAAALDH1A1CYP3A4 | |
| SCHEMBL22508001 | 0.82 | L3MBTL1 (0.47) | L3MBTL1POLBGAAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344571-B1 | Organic color center-tailored, semiconducting carbon nanotubes and their method of manufacture | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2025-07-01 | — | — | US | claimed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12344571-B1 | Organic color center-tailored, semiconducting carbon nanotubes and their method of manufacture | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3956033-B1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-8729091-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2603496-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| CN-103068806-A | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | SIENA BIOTECH SPA | 2013-04-24 | — | — | CN | disclosed |
| US-8420647-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2012019966-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) | 2012-02-09 | — | — | US | disclosed |
| WO-2011089099-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | disclosed |
| CN-101094854-A | Constrained compounds as cgrp-receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2007-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | L3MBTL1 3805/4885POLB 1611/4885GAA 1442/4885 |
| US-12103902-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | L3MBTL1 2253/4885POLB 1688/4885GAA 3686/4885 |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | L3MBTL1 4658/4885POLB 2965/4885GAA 2320/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | L3MBTL1 365/4885POLB 846/4885GAA 260/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | L3MBTL1 2853/4885POLB 3428/4885GAA 3195/4885 |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | L3MBTL1 3539/4885POLB 1873/4885GAA 28/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | L3MBTL1 539/4885POLB 3518/4885GAA 4/4885 |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | L3MBTL1 3805/4885POLB 1611/4885GAA 1442/4885 |
| US-12344571-B1 | Organic color center-tailored, semiconducting carbon nanotubes and their method of manufacture | NOS1, NOS3, NOS2 | L3MBTL1 2354/4885POLB 1001/4885GAA 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.